These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 31488205)
1. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205 [TBL] [Abstract][Full Text] [Related]
2. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. Abu-Sbeih H; Ali FS; Wang X; Mallepally N; Chen E; Altan M; Bresalier RS; Charabaty A; Dadu R; Jazaeri A; Lashner B; Wang Y J Immunother Cancer; 2019 Apr; 7(1):93. PubMed ID: 30940209 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410 [TBL] [Abstract][Full Text] [Related]
5. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study. Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. Zou F; Faleck D; Thomas A; Harris J; Satish D; Wang X; Charabaty A; Ernstoff MS; Glitza Oliva IC; Hanauer S; McQuade J; Obeid M; Shah A; Richards DM; Sharon E; Wolchok J; Thompson J; Wang Y J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34789551 [TBL] [Abstract][Full Text] [Related]
8. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161 [TBL] [Abstract][Full Text] [Related]
9. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis. Saji A; Chopra M; Jacob J; Altan M; Alhalabi O; Shah AY; Qiao W; Wang Y; Thomas A J Cancer Res Clin Oncol; 2023 Aug; 149(9):5841-5852. PubMed ID: 36585982 [TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. Gong Z; Wang Y JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703 [TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. Zou F; Wang X; Glitza Oliva IC; McQuade JL; Wang J; Zhang HC; Thompson JA; Thomas AS; Wang Y J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436487 [TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045 [TBL] [Abstract][Full Text] [Related]
14. Vasavada S; Panneerselvam K; Amin R; Varatharajalu K; Okhuysen PC; Oliva ICG; Wang J; Grivas P; Thomas AS; Wang Y Ann Gastroenterol; 2022; 35(4):393-399. PubMed ID: 35784625 [TBL] [Abstract][Full Text] [Related]
15. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Grover S; Dougan M; Tyan K; Giobbie-Hurder A; Blum SM; Ishizuka J; Qazi T; Elias R; Vora KB; Ruan AB; Martin-Doyle W; Manos M; Eastman L; Davis M; Gargano M; Haq R; Buchbinder EI; Sullivan RJ; Ott PA; Hodi FS; Rahma OE Cancer; 2020 Aug; 126(16):3758-3767. PubMed ID: 32567084 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview. Zoghbi M; Burk KJ; Haroun E; Saade M; Carreras MTC Support Care Cancer; 2024 Sep; 32(10):680. PubMed ID: 39311981 [TBL] [Abstract][Full Text] [Related]
17. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways. Sleiman J; Brand RM; Pai R; Brand RE; Rhee J; Schwartz M; Davar D Clin J Gastroenterol; 2023 Oct; 16(5):680-684. PubMed ID: 37452993 [TBL] [Abstract][Full Text] [Related]
18. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690 [TBL] [Abstract][Full Text] [Related]
19. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. Abu-Sbeih H; Ali FS; Luo W; Qiao W; Raju GS; Wang Y J Immunother Cancer; 2018 Sep; 6(1):95. PubMed ID: 30253811 [TBL] [Abstract][Full Text] [Related]